Naltrexone/bupropion

Drug Profile

Naltrexone/bupropion

Alternative Names: Bupropion/naltrexone; Contrave; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; NB32

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orexigen Therapeutics
  • Developer Biologix FZCo; Kwang Dong Pharmaceutical; Orexigen Therapeutics; Rovi; Valeant Pharmaceuticals International
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • No development reported Depressive disorders; Smoking withdrawal

Most Recent Events

  • 13 Oct 2017 United States District Court for the District of Delaware rules in favour of Orexigen Therapeutics in Paragraph IV litigation filed against Actavis Laboratories in USA
  • 07 Aug 2017 Naltrexone/bupropion market licensed to Cheplapharm Arzneimittel in Austria, France and Germany
  • 26 Jul 2017 Naltrexone/bupropion market licensed to Biologix in Egypt under an amendment to a commercialisation and distribution agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top